The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

25 Apr 2016 16:19

RNS Number : 2683W
Hikma Pharmaceuticals Plc
25 April 2016
 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

SAID DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 10,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

10,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£23.24p

14.

Date and place of transaction

 

25 APRIL 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

13,153,862 (5.49%) COMPRISING:

 

DIRECTLY, INCLUDING CONNECTED PERSONS: 657,000 (0.27%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 12,496,862 (5.22%)

16.

Date issuer informed of transaction

 

 

25 APRIL 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 25 April 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MAZEN DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 10,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

10,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£23.24p

14.

Date and place of transaction

 

25 APRIL 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

7,198,307 (3.01%) COMPRISING:

 

DIRECTLY: 907,041 (0.38%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 6,291,266 (2.63%)

16.

Date issuer informed of transaction

 

 

25 APRIL 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 25 April 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MOHAMMED 'ALI' AL-HUSRY

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 10,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

10,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£23.24p

14.

Date and place of transaction

 

25 APRIL 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

5,787,920 (2.42%) UNDER DYKB LIMITED COMPRISING:

 

DIRECTLY: 1,162,811 (0.49%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 4,625,109 (1.93%)

16.

Date issuer informed of transaction

 

 

25 APRIL 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 25 April 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBUGDSRBDBGLU
Date   Source Headline
13th Apr 202111:35 amRNSBlock listing Interim Review
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition
2nd Mar 20214:44 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:01 pmRNSDirector/PDMR Shareholding
25th Feb 20211:00 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSFinal Results
8th Feb 20212:55 pmRNSNotice of Results
26th Jan 20218:01 amRNSPotential Acquisition
15th Jan 20213:59 pmRNSHikma provides update on generic Advair Diskus®
13th Jan 20219:21 amRNSDirector/PDMR Shareholding
13th Jan 20219:14 amRNSDirector/PDMR Shareholding
18th Dec 202010:10 amRNSHolding(s) in Company
17th Dec 20205:30 pmRNSHikma launches generic Advair Diskus®
14th Dec 202012:57 pmRNSHolding(s) in Company
10th Dec 20204:00 pmRNSDirector/PDMR Shareholding
10th Dec 20203:51 pmRNSDirector/PDMR Shareholding
2nd Dec 20203:00 pmRNSTotal Voting Rights
2nd Dec 20201:05 pmRNSHolding(s) in Company
9th Nov 202011:38 amRNSHolding(s) in Company
5th Nov 202011:30 amRNSDirectorate Change
5th Nov 20207:00 amRNSHikma launches Icosapent Ethyl Capsules
5th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:20 pmRNSTotal Voting Rights
22nd Oct 20201:16 pmRNSNotice to Bondholders
8th Oct 20208:38 amRNSBlocklisting Application
1st Oct 202011:01 amRNSBlock listing Interim Review
22nd Sep 20207:00 amRNSHikma updates on ANDA for generic Advair Diskus®
3rd Sep 20203:15 pmRNSHikma receives favourable court ruling
2nd Sep 20209:30 amRNSTotal Voting Rights
7th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20202:25 pmRNSTotal Voting Rights
16th Jul 202012:06 pmRNSNotice of Results
7th Jul 202012:48 pmRNSPublication of Offering Circular
25th Jun 20204:12 pmRNSHolding(s) in Company
25th Jun 20201:00 pmRNSDirectorate Change
23rd Jun 20205:30 pmRNSHikma Pharmaceuticals
23rd Jun 202011:39 amRNSHolding(s) in Company
23rd Jun 20207:00 amRNSResult of placing in Hikma Pharmaceuticals PLC
23rd Jun 20207:00 amRNSTransaction in Own Shares
22nd Jun 20205:13 pmRNSTransaction in Own Shares
22nd Jun 20205:09 pmRNSProposed Placing in Hikma Pharmaceuticals PLC
22nd Jun 202011:24 amRNSDirector/PDMR Shareholding
22nd Jun 202011:22 amRNSDirector/PDMR Shareholding
22nd Jun 202011:20 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.